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Abstract—Unprecedented knowledge levels in life sciences
along with technological advances in micro- and nanotechnolo-
gies and microfluidics have recently conditioned the advent
of Lab-on-Chip (LoC) devices for In-Vitro Medical Testing
(IVMT). Combined with smart-mobile technologies, LoCs are
pervasively giving rise to opportunities to better diagnose
disease, predict and monitor personalised treatment efficacy,
or provide healthcare decision-making support at the Point-
of-Care (PoC). Although made increasingly available to the
consumer market, the adoption of LoC-based PoC In-Vitro
Medical Testing (IVMT) systems is still in its infancy. This
attrition partly pertains to the intricacy of designing and de-
veloping complex systems, destined to be used sporadically, in a
fast-pace evolving technological paradigm. System evolvability
is therefore key in the design process and constitutes the main
motivation for this work.
We introduce a smart-mobile and LoC-based system archi-
tecture designed for evolvability. By propagating LoC pro-
grammability, instrumentation, and control tools to the high-
level abstraction smart-mobile software layer, our architecture
facilitates the realisation of new use-cases and the accom-
modation for incremental LoC-technology developments. We
demonstrate these features with an implementation allowing
the interfacing of LoCs embedding current- or impedance-
based biosensors such as Silicon Nanowire Field Effect Tran-
sistors (SiNW-FETs) or electrochemical transducers. Structural
modifications of these LoCs or changes in their specific opera-
tion may be addressed by the sole reengineering of the mobile-
software layer, minimising system upgrade development and
validation costs and efforts.
Keywords-Lab-on-Chip; Smartphone; Point-of-Care; In-
Vitro Medical Diagnostics; System Evolvability; System Ar-
chitecting;
I. INTRODUCTION
A. The healthcare landscape and Point-of-Care in-vitro
medical testing (IVMT)
The healthcare landscape of our modern societies is
rapidly changing. The increasing healthcare demand of the
Western World’s aging population stretches the restricted
budgets of our institutions and challenges the limited avail-
ability of our care personnel and facilities. Chronic diseases
hold a particular place in that scenery. By accounting to
up to 84% of the annual 3 trillion dollars of healthcare
expenditures in the United States [1], conditions like cancer,
heart-failure or neurodegenerative diseases are not only
debilitating but also represent a significant economic burden,
threatening health accessibility and quality of care. In the
developing world, infectious diseases like HIV/AIDS or
tuberculosis remain a predominant cause of death mainly
on the account of insufficient resources and infrastructures
[2], [3].
Despite these worrisome observations, unprecedented
knowledge levels in life science, especially in the -omics
disciplines (genomics, transcriptomics, proteomics, etc. [4])
and recent technological advances are radically changing
both the way and efficacy with which we diagnose and
tackle disease. Medical diagnostics, therapeutics and clinical
management are all being remodelled in an attempt to
personalise medicine and empower patients with tools to
become prominent contributors of their own health manage-
ment. [1], [5].
More specifically, in-vitro medical testing (IVMT) plays a
preponderant role in the identification of disease, helping
the initiation of appropriate therapy and allowing the fur-
ther monitoring of treatment outcome. Initially driven by
a centralized, technical, high-throughput biological sample
analysis process, the quantification of analytes in biological
samples is undergoing a major paradigm shift, transitioning
to a diagnostician and patient-oriented Point-of-Care (PoC)
decision-making support system. This revolution has been
made possible by advances in nanotechnology, microflu-
idics, and biosensing, which combined, have conditioned
the advent of Lab-on-Chip (LoC) technologies and systems.
LoCs are designed to embed most of the functionalities of a
central chemical and biological analyses laboratory on chips
with footprints rarely larger than a few centimetres square.
They allow for routines tests to be performed using sample
volumes down to a few nanoliters. LoC techniques enable
PoC in-vitro testing, potentially empowering diagnosticians
and patients to carry out automated screening, diagnostics
or monitoring procedures outside of the clinical setting.
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Figure 1. LoC-based PoC smart-mobile IVMT concept. In simplified cases, if no fluid actuation is required (e.g. for glucose monitoring), the analytical
process starts from the LoC with the biological sample making its way to the LoC biosensor, the HWA then handles signal acquisition and processing
before transmitting the results to the smart-device. Simple analytics such as mathematical fitting to a calibration curve is either handled in the HWA or
the smart-device before results are fed back to the end-user.
LoC devices ubiquitously rely on microfluidic technology
to carry out on-chip processing of the biological sample (e.g.
blood, saliva, etc.). Some of the most common microflu-
idic functions include the separation, pre-concentration, and
isolation of the analytes of interest [6]–[8]. The operation
of specific biosensing schemes enables the extraction of
the relevant predictive information. Detection methods re-
lying on optical [9], electrochemical [10], or impedimetric
phenomema [11] are examples of the wide spectrum of
technologies that can be leveraged in applications ranging
from the determination of immunoprotein biomarkers con-
centrations [12] to cell sorting [13] or rare cell isolation
[14], and to single-cell [15] or single-molecule analysis [16].
Benefiting from recent progress in solid-state nanopores,
-omics-sequencing techniques have emerged in the PoC
paradigm [17]. Drastic reductions in cost-per sequenced
base-pair [18] along with progresses in -omics big-data
analytics [19] are promising a new range of applications
to make their way to consumer-products. Cancer molecular
diagnostics but also pathogen identification or drug-response
profiling are just a few examples [4].
The complexity of LoC systems can be substantial, espe-
cially when flow actuation for biological sample processing
is instrumented such as for digital- [20] or droplet-based [21]
microfluidic systems or when addressing complex sensing
mechanisms (e.g. fluorescence, mass spectrometry, etc.).
Instrumentation complexity (e.g. hardware, optics, control
algorithms, etc.) and costs have been arguably considered a
limitation to the adoption of advanced LoCs in PoC settings,
notably in the developing world [22].
B. IMVT and smart-mobile technology
Another key factor in recent patient-empowerment and
the remodelling of our healthcare landscape is the advent
of smart mobile technology. Smart-phones and tablets are
already providing widely adopted mobile-health software
solutions, ranging from image-analysis-based dermatologic
evaluation [23] to applications helping patients to better
adhere to their pharmacological treatment [24]. More re-
cently, numerous physical activity tracking applications have
emerged from the upcoming of smart-sensors and wearables,
allowing the monitoring of basic health-metrics such as heart
rate, blood pressure, or body-mass index. These biological
signals are known to strongly correlate with disease severity
for conditions such as hypertension or cardiac arrhythmias.
They represent in those cases valuable surrogate biomarkers
and validated clinical endpoints that can be evaluated to
assess treatment efficacy or prognosis.
These applications illustrate how smart-devices can be lever-
aged for their peripherals, wireless interfaces, computational
power, software flexibility, cloud connectivity, or simply for
the possibilities they offer in terms of user-experience. These
features constitute as many opportunities in attempting to
cope with the limitations of instrumented-LoC technologies
in a PoC context. Smart-mobile technology can indeed be
used to address complex sample handling flow actuation [25]
or to interface elaborate sensing technologies for quantitative
analyses. Some notable recent successes include the reliable
PoC diagnosis of HIV and syphilis in less than 15 minutes
in a low-income country using a LoC-dongle [26], [27]. Al-
though this example represents a milestone in the upcoming
advent of such systems, their adoption today remains scarce,
with the notable exception of glucose monitoring and of a
few general inflammation and hormonal biomarkers [28].
Pertaining to this slow democratisation, it has been argued
that the instrument and consumable business model is, in
the consumer market, limited by low frequency of use
[29]. If unlike glucose-monitoring, IVMT tests need only be
performed sporadically, high average cost-per-test is likely
to result from the initial investment for the instrument
and from the low-volume, and therefore pricy consumables
(LoCs). This limitation is substantial and raises the critical
question of what specific design issues need to be addressed
in order to ensure that the development, validation and
commercialisation of these systems can be profitable and
thus to guarantee their societal impact.
II. LOC-BASED POC IVMT SYSTEMS AND
EVOLVABILITY
A. Evolvability as a design requirement
While more than 150.000 scientific publications discuss
the predictive values of thousands of potential biomarkers
for disease diagnosis or therapy effectiveness assessment,
only about a hundred are currently validated for use in clin-
ical practice [30]. Our increasing understanding of disease
mechanisms will yet much likely result in the validation
of other candidate molecules [31]. Concurrently, technolog-
ical developments in LoC technologies (e.g. microfluidics,
biosensing, etc.), advanced computational tools for LoC
design and operation [32] and progress in -omics-based
predictive analytics will give rise to new potential LoC-
based PoC IVMT applications and help achieve greater
systems performances. Leveraging these opportunities will
yet necessitate addressing greater system complexity. Blank-
canvas full system design will steadily translate into higher
implementation and validation costs and efforts, along with
greater risks associated with longer time-to-market. Complex
LoC-based PoC IVMT will thus increasingly benefit from
system evolvability.
System evolvability can be defined as “the capacity of
a system to successfully adapt to changing requirements
throughout its lifecycle without compromising architectural
integrity. [...] meet the new needs of the customer in a more
cost effective manner than developing a new system” [33].
System evolvability should minimise the costs and efforts
associated with system re-design and with development iter-
ations of hardware, software and interfaces. It will facilitate
system maintainability and promote system legacy, the latter
of which we identified as an important factor for success
in a low frequency-of-use instrument/consumable business
model.
B. Smart-device and LoC-based system evolvability criteria
LoC devices were originally application-specific (i.e. op-
erated in a fixed manner to realise a given use-case: bi-
ological sample processing and data acquisition schemes
were mostly determined at the LoC design-stage). Bene-
fiting to LoC-based systems evolvability, configurable or
programmable LoCs have recently emerged [34], [35]. They
enable the realisation of custom biological sample process-
ing functions or the characterisation of chosen fluid or
analytes properties depending on the use-case of interest.
They require to that end the generation of specific LoC
programs, determining the actuation (e.g. via micro-valves,
pumps or electrowetting) and acquisition schemes (e.g.
sensor excitation and readout) necessary to realise these
functions. The increasing complexity of reprogrammable
LoC devices puts stringent requirements on LoC control and
instrumentation hardware and software. Programming and
program execution handling tools are necessary in order to
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Figure 2. Evolvable system architecture diagram - A mobile-software API
allows for the generation of custom pre-compiled or run-time LoC programs
to be integrated in an application’s data model. Low-level tasks, relying on
the API instrumentation and control drivers are translated to HWA/LoC
instructions through a compiler object (left part of the diagram). Low-level
task execution is handled at the mobile-software layer but realised in lower-
level embedded-software, resulting in appropriate LoC actuation or sensor
excitation. Biosensing data is acquired at the HWA layer and transmitted
back to mobile-software, through a decoder object, for analytics, storage,
user-interfacing, etc.
derive, fetch and translate the relevant sequences of actuation
or acquisition instructions to the LoC instrumentation and
control drivers.
When a smart-device is coupled to an instrumented LoC-
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Figure 3. LoC software model: The abstracted LoC is specified according to the architecture and configuration of the specific physical LoC to be interfaced
to the HWA. These properties consist of an array of biosensors or actuators of various types, each physically mapped to the I/O terminals of the HWA. The
abstracted-LoC also comprehends references to an array of LoC-programs each helping to realise a PoC IVMT use-case. These programs are composed of
intertwined low-level routines (performed in the HWA or the LoC, e.g. lock-in amplification acquisition) or high-level tasks (e.g. data analytics) realised
in mobile-software or in the cloud.
based system, instrumentation and control functions are
most often allocated to a specifically designed hardware
accessory (HWA) interfaced to the smart-device via a con-
nector (dongle-accessory) or wirelessly. LoCs are physically
interfaced to the HWA during LoC program execution,
and later disposed of (single-use LoCs are predominant in
IVMT applications to avoid biological fouling and resulting
reliability issues). This system architecture predominantly
involves the design and execution of the LoC programs
at the HWA embedded-software/hardware abstraction layer,
leaving the smart-device mostly responsible for higher-level
software data analytics and user-interfacing (Fig. 1). While
this design may provide several advantages (e.g. real-time
system requirements management) it shows limited evolv-
ability. The implementation of new LoC programs will not
only require low-level embedded-software/hardware reengi-
neering but also necessarily, to a certain extent, the partial
reshaping of higher-level mobile software. The concurrent
efforts to redesign both lower- and higher-level system layers
will also require engineering team coordination to rethink
the different software-layers interfaces and to eventually
validate their integration. These activities will cost time and
resources, hindering the realisation and further adoption of
the new use-case or technology.
Taking into account these considerations, we suggest instead
an architecture propagating LoC programability and the
LoC instrumentation and control tools to mobile-software,
concentrating design and engineering efforts at higher-
abstraction layers (Fig. 2). We present the design and im-
plementation of such a system capable of interfacing LoCs
embedding current- or impedance-based biosensors such as
Silicon Nanowire Field Effect Transistors (SiNW-FET) [36]
or electrochemical transducers [37]–[40].
III. A SMARTPHONE-BASED DIAGNOSTICS PLATFORM
DESIGNED FOR EVOLVABILITY
A. System design overview
The design of our platform involved the abstraction and
compartmentalisation of a generic LoC device embedding
an arbitrary number of cells (e.g. biosensors or actuators).
These are specified by their type and their physical mapping
on the LoC (The software model of the LoC is given in
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Figure 4. Program execution subsystem allocation - Execution is controlled by the smart-device. Low-level tasks intructions are fetched and transmitted
to the HWA which then relays the appropriate sensing or actuation schemes to the LoC. Acquisition data can be preprocessed in the HWA or transmitted
directly back to the smart-device for post-processing and analysis. Results from high-level routines performed upon low-level tasks completion can be used
in program conditional branching before the next instruction is fetched to the HWA.
Fig. 3). We then determined the instrumentation and control
requirements with regards to each possible cell (sensor
excitation, acquisitions, actuation, etc.) and used them to
objectify drivers in mobile-software. Concurrently, we de-
signed the instrument/reader HWA as well as the interfaces
and communication protocols necessary to translate higher-
level mobile-software instructions to downstream embedded-
software routines and to enable the upstream transmission
of pre-processed or raw acquisition data from the HWA to
mobile-software.
B. System architecture
Our system architecture revolves around an iOS Ap-
plication Programming Interface (API) providing a high-
level smart-mobile software toolbox for the design of LoC
programs.
1) API: The API allows for the pre-compiled or run-
time generation of specific LoC programs, adapted to the
architecture of the LoC interfaced to the HWA. These LoC
programs are executed from the mobile-software layer. An
illustration of the software data model for the LoC, some of
its possible constituents and their properties is given in Fig.
3.
LoC programs usually consist of low-level tasks, typically
acquisition sequences, that rely on the instrumentation and
control drivers objectified in iOS. These drivers enable
the configuration of voltage waveform excitations, tunable
acquisitions of DC currents or the phase-sensitive detection
and recovery of AC currents (i.e. Lock-in amplification
[41], [42]). They also allow the programming of specific
HWA post-processing routines such as low-pass FIR filtering
and decimation. These low-level tasks can then be called
on appropriate LoC cells (sensor or actuator) in a timely
manner. No actuation driver was considered within the
scope of this work but their design and implementation can
be envisaged without the need to alter the overall system
architecture.
The API also comprehends high-level classes and methods
that can virtually consist of any high-level related task: from
the call of cloud-computing analytics, to database access,
information storage or simple software delays. These high-
level tasks can be intertwined with low-level tasks when
composing a LoC program.
Finally LoC program generation and execution handling
classes and methods were designed to leverage the afore-
mentioned low- or high-level tasks when designing use-case
specific LoC programs. A compiler and a decoder object
provide the interfaces necessary to relay LoC-based task
instructions and data to or from the HWA.
2) Instrument hardware-accessory: The HWA’s ar-
chitecture revolves around a Central Processing Unit
(TMS320F28377D - C2000 Digital Signal Controller, Texas
Instruments Inc.). In our case, the HWA CPU embeds
the peripherals necessary to achieve tunable voltage wave-
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LoC 
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Figure 5. System hardware setup and iOS mobile application storyboard: From the left: LoC configuration: Define the architecture and configuration of
the LoC physically interfaced to the HWA; Low-level tasks definition: Select and customise the low-level routines for acquisitions and/or actuation, map
them to the relevant biosensors or actuators previously defined; Program generation: Select either low- or high-level task to define the sequence forming the
LoC program, call compilation and execution; Results: Illustration of the lock-in amplification acquisition routine performed on a SiNW-FET at 20Hz, The
steps in the impedance magnitude correspond to steps in the electrical potential applied to the gate, simulating target biomarker concentration variations.
The HWA materializes at this early development stage by a development board hosting the HWA CPU (TI C2000 TMS320F28377D DSC) interfaced to
a break-out PCB embedding the analog signal conditioning circuitry and the BLE module. This PCB is here interfaced to a LoC baring SiNWs. The LoC
is plugged to another interface-PCB via a zero-insertion force socket. SMA connectors are wiring the adequate LoC terminals to the relevant HWA I/Os.
forms excitations (12-bit DAC or PWM channels) and
multiplexed analog-to-digital conversions (12 multiplexed
inputs to ADC modules). Embedded-software routines were
implemented to allow for asynchronous or synchronous
excitations/acquisitions in order to achieve phase-sensitive
detection and the recovery of small AC-signals. The HWA
CPU is slave to a Bluetooth Low Energy (BLE) mod-
ule (BLE112, Bluegiga Inc.) allowing wireless interfac-
ing with iOS. Appropriate signal conditioning circuitry is
following the DAC and PWM excitation outputs (recon-
struction low-pass filters) or precedes the ADC sample-
and-hold circuitry (transimpedance current-amplifiers with
programmable gains followed by antialiasing filters). LoC
interfacing is, at this early development stage, achieved via
coaxial SMA cables adequately connecting the embedded
LoC sensors to the chosen HWA I/Os (Fig. 5).
IV. OPERATION
We designed and implemented a simple iOS mobile
application to demonstrate the functionalities of our system
prototype. The application user-interface (UI) is built on a
tab bar menu. The first tab item presents the embedded-cells
(sensors or actuators) specified for the LoC software model.
There, the user should set up the LoC cells so that they
reflect the architecture and physical mapping of the specific
LoC interfaced to the HWA.
The second tab item allows the configuration of excita-
tions or acquisition sequences along with post-processing
routines, mapping them to the relevant cells defined in the
previous step. The low-level tasks customisation scene in
Fig. 5 presents the configuration of a lock-in amplification
acquisition sequence for monitoring both impedance mag-
nitude and phase of a SiNW-FET. These settings include
in particular the current-amplifier gain selection, the AC
excitation frequency, the excitation amplitude, the number
of acquisition periods, the post-decimation sampling rate
and the FIR low-pass filter. Other low-level tasks enable
independent customisable current-acquisitions (e.g. for pho-
todiodes sensors), or simple voltage excitations. Classes and
methods for electrochemical measurements such as cyclic
voltametry, amperometry, square-wave cyclic voltametry or
electrochemical impedance spectroscopy have not been im-
plemented but are hardware-ready.
The third tab item presents examples of pre-programmed
high-level tasks. While the possibilities there are almost
unlimited, we implemented simple mobile software delays
that can easily be incorporated in a LoC program, for
instance those that require latencies between acquisitions.
Finally the fourth tab item enables LoC program generation
by sequencing either of the previously defined low- or
high-level tasks, such as a lock-in amplification acquisition
on the first sensor mapped on the LoC, followed by a
two-second software delay, followed by a simple sinewave
voltage excitation on the third cell mapped on the LoC, etc.
Once a LoC program has been configured, a compilation
step is necessary before starting execution. The program
tasks are then executed sequentially, the completion of data
acquisition for one task triggering the next one (Fig. 4).
A capture of the drain-source impedance magnitude of a
SiNW-FET, recovered by lock-in amplification at 20Hz is
presented at the right of Fig. 5
V. DISCUSSION
The system architecture we propose in this work offers
significant system evolvability: The iOS mobile application
presented before illustrates the capability of our platform
to interface various LoCs embedding a variable number of
current- or impedance-based biosensors, potentially targeting
different biomarkers. Although the API does not include
any actuation drivers at this stage, the available acquisitions
schemes make it possible to interface varied passive mi-
crofluidic devices, driven by capillary flow. Interfacing these
devices will necessitate no or only minor HWA embedded-
software upgrades therefore concentrating the development
efforts at the mobile-software layer.
Our system architecture also applies for use-cases or LoCs
of higher complexity. An example could be that of LoCs
embedding their own processing unit: This is becoming
increasingly common as the high-level of integration of
micro- and nanobiosensors or MEMS often requires the
development of complete System-on-Chips (SoC) [43]. This
scenario would simply require the design and implemen-
tation of additional mobile-software drivers most likely
involving the configuration and control of the HWA CPU
communication modules (SPI, I2C) without compromising
the integrity of the overall system architecture.
The instrumentation and control drivers, coupled to mobile-
software handling of LoC program execution, enable the
retrieval of low-level acquisition data from the execution
of the LoC program low-level tasks. This design feature
provides significant freedom of action as to how to post-
process the data in higher-level abstraction layers: in mobile-
software or potentially in the cloud. This property is valuable
in a context where -omics sequencing technologies are
increasingly coupled to cloud supercomputing analytics [19].
Similarly, the composition of LoC programs intertwining
low- and high-level tasks offer significant LoC programma-
bility advantages : high-level tasks return values can be
used to modify following LoC program instructions at run
time. LoC program conditional branching could thus rely
on the evaluation of user-queried or cloud-computing return
properties.
Beyond LoC structural or functional modifications, our
architecture could also offer significant evolvability ad-
vantages should the HWA itself need to be partially or
fully redesigned, for instance to accommodate for different
actuation or biosensing mechanisms. The overall high-level
mobile-software architecture could be preserved to some ex-
tent, implying that the modularity of our system may extend
not only to the LoCs but to the instrument/reader HWA. This
would in turn promise a wide range of applications and use-
cases all founded on the same high-level software abstraction
layer.
Our investigation mainly addressed system evolvability and
did not include considerations such as embedded-software
real-time system capabilities, system interoperability, regu-
latory requirements, etc. These elements all contribute to the
socio-technical complexity of the PoC IVMT system context
and may justify a more systematic and cross-disciplinary
approach to system analysis and design, such as Model-
Based Systems Engineering (MBSE).
VI. CONCLUSION
We presented in this work a LoC-based PoC IVMT
system architecture designed for evolvability. Relying on
LoC programmability and higher-abstraction software layers
flexibility, this architecture enabled us to implement a system
prototype allowing at this early development stage, the inter-
facing of various LoCs embedding current- or impedance-
based biosensors. Despite the challenges associated with
a highly complex socio-technical system context and the
current lack of clear LoC-based PoC IVMT system design
methodologies, we believe that such a design for evolvability
can promote end-user system adoption. We also conjecture
that most of the observations and some of the architectural
features evoked in this work may not only apply to LoC-
based PoC IVMT systems but also to the emerging Lab-in-
a-Body systems and applications [44]–[46].
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